Space is the place, man
SLS is positioned for very positive trial readout results in the coming months with 78 of 80 events reached. Author expects positive results and a potential buyout within the next year.
1d—
3d—
1w+19.7%
1m—
3m—
6m—
1y—
$SLS
3 thesesbullish 100%neutral 0%bearish 0%
Avg return (6m)
—
Win rate (6m)
— (0 resolved)
Recent theses
“full port, mix of call options with varying expirations (referenced leaps and closer-dated positions, screenshot shown but specific strikes/dates not legible in text)”
All in on cancer $SLS
SLS's GPS drug REGAL trial is near completion (78/80 events) and the author expects a positive outcome based on strong Phase 2 CR2 AML data showing 16.3 months vs 5.4 months median overall survival. Author is fully committed to the position, betting the trial success will drive stock sharply higher.
1d-15.7%
3d-13.3%
1w-4.3%
1m—
3m—
6m—
1y—
“LEAPS”
Options changed my life pt.5
SLS offers a high-risk, high-reward opportunity with potential 20x upside using LEAPS, representing a speculative bet on the company's success with binary outcome.
1d—
3d+4.8%
1w+41.3%
1m—
3m—
6m—
1y—
End of results.